X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (110) 110
humans (99) 99
female (69) 69
osteogenesis imperfecta (65) 65
bisphosphonates (60) 60
diphosphonates - therapeutic use (58) 58
osteoporosis (56) 56
endocrinology & metabolism (55) 55
male (53) 53
children (52) 52
osteogenesis imperfecta - drug therapy (44) 44
diphosphonates - administration & dosage (37) 37
bone density conservation agents - therapeutic use (36) 36
child (35) 35
fractures (34) 34
bone-mineral density (33) 33
adolescents (30) 30
bone density - drug effects (29) 29
neridronate (27) 27
treatment outcome (27) 27
adolescent (26) 26
bone density (26) 26
intravenous pamidronate (26) 26
orthopedics (26) 26
rheumatology (26) 26
therapy (26) 26
child, preschool (25) 25
medicine & public health (25) 25
middle aged (25) 25
zoledronic acid (24) 24
intravenous neridronate (23) 23
pamidronate (23) 23
adult (22) 22
aged (21) 21
bisphosphonate (21) 21
bone (21) 21
bone density conservation agents - administration & dosage (21) 21
collagen (21) 21
endocrinology (20) 20
infusions, intravenous (20) 20
pediatrics (20) 20
alendronate (19) 19
bone mineral density (18) 18
bones (18) 18
diphosphonates - adverse effects (18) 18
intravenous pamidronate treatment (18) 18
diphosphonates (17) 17
osteoporosis - drug therapy (17) 17
density (16) 16
risedronate (16) 16
injections, intravenous (15) 15
abridged index medicus (14) 14
mutation (14) 14
care and treatment (13) 13
double-blind (13) 13
oral alendronate (13) 13
osteogenesis imperfecta - physiopathology (13) 13
pain (13) 13
research (13) 13
diphosphonates - pharmacology (12) 12
fractures, bone - prevention & control (12) 12
intravenous administration (12) 12
bisphosphonate treatment (11) 11
follow-up studies (11) 11
patients (11) 11
bone density conservation agents - adverse effects (10) 10
bone diseases (10) 10
drug administration schedule (10) 10
drug therapy (10) 10
infant (10) 10
internal medicine (10) 10
osteogenesis (10) 10
osteogenesis imperfecta - genetics (10) 10
time factors (10) 10
absorptiometry, photon (9) 9
adults (9) 9
osteogenesis imperfecta - complications (9) 9
osteoporosis, postmenopausal - drug therapy (9) 9
pagets-disease (9) 9
pamidronate treatment (9) 9
pharmacology & pharmacy (9) 9
placebo-controlled trial (9) 9
vertebral fractures (9) 9
79778-41-9 (8) 8
administration, oral (8) 8
alkaline phosphatase - blood (8) 8
biomarkers - blood (8) 8
bone density conservation agents (8) 8
bone resorption (8) 8
bone resorption - drug therapy (8) 8
bone turnover (8) 8
controlled-trial (8) 8
diagnosis (8) 8
disease (8) 8
osteogenesis imperfecta - pathology (8) 8
phosphonates (8) 8
postmenopausal osteoporosis (8) 8
postmenopausal women (8) 8
radiography (8) 8
risk factors (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 07/2012, Volume 158, Issue 2, pp. 274 - 282
Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open‐label study, 118 adults with... 
bone mineral density | pain | bisphosphonates | thalassaemia | osteoporosis | Thalassaemia | Osteoporosis | Bone mineral density | Pain | Bisphosphonates | YOUNG-ADULTS | IQOLA PROJECT | INTRAMUSCULAR NERIDRONATE | WOMEN | INTRAVENOUS ZOLEDRONIC ACID | DISEASE | REPLACEMENT THERAPY | OSTEOGENESIS IMPERFECTA | PLACEBO-CONTROLLED TRIAL | HEMATOLOGY | HEALTH SURVEY | Collagen Type I - blood | Peptides - blood | Humans | Middle Aged | Male | Osteoporosis - drug therapy | beta-Thalassemia - complications | Osteoporosis - etiology | Bone Remodeling - drug effects | Young Adult | Back Pain - prevention & control | Diphosphonates - therapeutic use | Adult | Female | Diphosphonates - adverse effects | Osteoporosis - physiopathology | Alkaline Phosphatase - blood | Lumbar Vertebrae - physiopathology | Back Pain - etiology | Bone Density Conservation Agents - adverse effects | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Biomarkers - blood | Bone Density - drug effects | Adolescent | Hip Joint - physiopathology | Quality of Life | Femur Neck - physiopathology | Alkaline phosphatase | Surgical implants | Back pain | Collagen (type I) | Calcium | Spine | Spine (lumbar) | Patients | Hip | Quality of life | Bone resorption | Randomization | Vitamin D | Collagen | Biocompatibility | Bone density | Hormone replacement therapy | Adults | Neridronic acid | Index Medicus
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue Suppl 2, p. 1627
BackgroundBone Marrow Oedema Syndrome (BMES) is a severely disabling pain syndrome without a definite treatment well established.ObjectivesThe aim of this... 
Edema | Pain | Intravenous administration | Magnetic resonance imaging | Bone marrow | Patients | Bisphosphonates | Neridronic acid
Journal Article
Osteoporosis International, ISSN 0937-941X, 11/2017, Volume 28, Issue 11, pp. 3277 - 3280
Journal Article
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 03/2011, Volume 26, Issue 3, pp. 512 - 518
Journal Article
Journal of Bone and Mineral Metabolism, ISSN 0914-8779, 7/2012, Volume 30, Issue 4, pp. 434 - 438
Journal Article